Evidence map›Paper›PMID 33677674›Full record

ArticleCancer chemotherapy and pharmacology2021

Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.

Sarah M Kashanian, Noa G Holtzman, Ciera L Patzke, Jonathan Cornu, Alison Duffy, Madhurima Koka, Sandrine Niyongere, Vu H Duong, Maria R Baer, Jummai Apata and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Anticoagulants in hematologic malignancies: what is the data?Hematology. American Society of Hematology. Education Program · 2025
    Review
  2. Novel Therapeutic Approaches in Pediatric Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Sarah M KashanianDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Noa G HoltzmanImmune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-5706-1109
Ciera L PatzkeGreenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 22 South Greene Street, Room N9E06, Baltimore, MD, 21201, USA.ORCID 0000-0002-8566-4345
Jonathan CornuDepartment of Pharmacy, University of Maryland Medical Center, Baltimore, MD, USA.
Alison DuffyGreenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 22 South Greene Street, Room N9E06, Baltimore, MD, 21201, USA.ORCID 0000-0002-9018-3722
Madhurima KokaDepartment of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-0457-8489
Sandrine NiyongereDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-9254-0095
Vu H DuongDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-0278-7727
Maria R BaerDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-9499-1348
Jummai ApataCenter for Urban Health Disparities Research and Innovation, Morgan State University, Baltimore, MD, USA.ORCID 0000-0001-6733-6914
Farin KamangarDepartment of Biology, School of Computer, Mathematical, and Natural Sciences, Morgan State University, Baltimore, MD, USA.ORCID 0000-0003-4169-7978
Ashkan EmadiDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. aemadi@umm.edu.ORCID 0000-0003-3769-3210
University of Maryland, Baltimore · USMorgan State University · US

Funding

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center P30CA134274
6 · The paper itself

Abstract

purposeAsparaginases, key agents in treatment of acute lymphoblastic leukemia (ALL), are associated with venous thromboembolism (VTE). While risks of short-acting asparaginase-related VTE is well-known, we studied VTE incidence and risk factors in adult ALL patients treated with and without long-acting pegylated asparaginase (PegA).

methodsSingle-center, retrospective analysis of 89 ALL patients treated with (n = 61) or without (n = 28) PegA at Greenebaum Comprehensive Cancer Center. Reviewed patient and disease characteristics, treatment, and VTE incidence.

resultsVTE during treatment occurred in 31 patients (35%), and was associated with PegA (p = 0.001) and Philadelphia chromosome negativity (p = 0.002). Among PegA recipients, VTE was associated with a significantly higher mean body mass index (BMI) of 31.3 kg/m

conclusionThis study confirms PegA as a risk factor for VTE in patients with ALL. Risk factors among those receiving PegA include higher BMI and pre-T/T cell ALL. ATIII repletion was not shown to be protective against VTE. There was a higher incidence of VTE in patients who received PegA with non-O compared to O blood type, but the precise correlation is uncertain.

Indexed as

Acute DiseaseAdolescentAdultAgedAged, 80 and overAntineoplastic AgentsAntithrombin IIIAsparaginaseB-LymphocytesBody Mass IndexEscherichia coliFemaleHumansIncidenceMaleMiddle AgedAntineoplastic AgentsAntithrombin IIIAsparaginaseAcute lymphoblastic leukemiaALLPegaspargasePegylated-asparaginaseVenous thromboembolism

Identifiers

PMID33677674
OpenAlexW3134224154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.